Jump to content

TACSTD2: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
ce
m v2.05b - Bot T20 CW#61 - Fix errors for CW project (Reference before punctuation)
 
(22 intermediate revisions by 15 users not shown)
Line 1: Line 1:
{{Short description|Protein-coding gene in the species Homo sapiens}}
{{PBB|geneid=4070}}
{{Infobox_gene}}
'''Tumor-associated calcium signal transducer 2''' is a [[protein]] that in humans is encoded by the ''TACSTD2'' [[gene]].<ref name="pmid8382772">{{cite journal | author = Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, Druck T, Huebner K | title = Retroposition in a family of carcinoma-associated antigen genes | journal = Mol Cell Biol | volume = 13 | issue = 3 | pages = 1507–15 |date=Apr 1993 | pmid = 8382772 | pmc = 359462 | doi = }}</ref><ref name="pmid11306819">{{cite journal | author = Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S | title = Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization | journal = Cytogenet Cell Genet | volume = 92 | issue = 1-2 | pages = 164–5 |date=Apr 2001 | pmid = 11306819 | pmc = | doi =10.1159/000056891 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: TACSTD2 tumor-associated calcium signal transducer 2| url = http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4070| accessdate = }}</ref>
'''Tumor-associated calcium signal transducer 2''', also known as '''Trop-2''' and as '''epithelial glycoprotein-1''' antigen (EGP-1)<ref>Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy [http://globenewswire.com/news-release/2015/01/05/694944/10113907/en/Immunomedics-Awarded-Fast-Track-Designation-by-FDA-for-Sacituzumab-Govitecan-IMMU-132-for-Triple-Negative-Breast-Cancer-Therapy.html]</ref> is a [[protein]] that in humans is encoded by the ''TACSTD2'' [[gene]].<ref name="pmid8382772">{{cite journal | vauthors = Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, Druck T, Huebner K | display-authors = 6 | title = Retroposition in a family of carcinoma-associated antigen genes | journal = Molecular and Cellular Biology | volume = 13 | issue = 3 | pages = 1507–1515 | date = March 1993 | pmid = 8382772 | pmc = 359462 | doi = 10.1128/MCB.13.3.1507 }}</ref><ref name="pmid11306819">{{cite journal | vauthors = Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S | title = Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization | journal = Cytogenetics and Cell Genetics | volume = 92 | issue = 1–2 | pages = 164–165 | date = Apr 2001 | pmid = 11306819 | doi = 10.1159/000056891 | s2cid = 9708614 }}</ref><ref name="entrez">{{cite web | title = Entrez Gene: TACSTD2 tumor-associated calcium signal transducer 2| url = https://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=4070}}</ref>


This [[intron]]less gene encodes a carcinoma-associated [[antigen]] defined by the monoclonal antibody [[GA733]]. This antigen is a member of a family including at least two type I [[membrane protein]]s. It transduces an intracellular [[calcium]] signal and acts as a [[cell surface receptor]].
This [[intron]]less gene is located at the short arm of chromosome 1 (1p32.1).<ref name=":1">{{Cite journal |last1=Wen |first1=Ying |last2=Ouyang |first2=Dengjie |last3=Zou |first3=Qiongyan |last4=Chen |first4=Qitong |last5=Luo |first5=Na |last6=He |first6=Hongye |last7=Anwar |first7=Munawar |last8=Yi |first8=Wenjun |date=December 2022 |title=A literature review of the promising future of TROP2: a potential drug therapy target |journal=Annals of Translational Medicine |volume=10 |issue=24 |pages=1403 |doi=10.21037/atm-22-5976 |doi-access=free |issn=2305-5839 |pmc=9843409 |pmid=36660684}}</ref> It encodes a carcinoma-associated [[antigen]] defined by the monoclonal antibody [[GA733]]. This antigen is a member of a family including at least two type I [[membrane protein]]s. It transduces an intracellular [[calcium]] signal and acts as a [[cell surface receptor]].


Mutations of this gene result in [[gelatinous drop-like corneal dystrophy]], an [[autosomal recessive]] disorder characterized by severe corneal [[amyloidosis]] leading to [[blindness]].<ref name="entrez"/>
Mutations of this gene result in [[gelatinous drop-like corneal dystrophy]], an [[autosomal recessive]] disorder characterized by severe corneal [[amyloidosis]] leading to [[blindness]].<ref name="entrez"/>


Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g., lung). Later, its expression was also described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.<ref name=":0">{{cite journal | vauthors = Vranic S, Gatalica Z | title = Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers | journal = Bosnian Journal of Basic Medical Sciences | volume = 22 | issue = 1 | pages = 14–21 | date = February 2022 | pmid = 34181512 | pmc = 8860310 | doi = 10.17305/bjbms.2021.6100 }}</ref>
This antigen is the target of [[sacituzumab govitecan]], an [[antibody-drug conjugate]].


Trop-2 plays a role in tumor progression by actively interacting with several key molecular signaling pathways traditionally associated with cancer development and progression. Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers. Trop-2 expression has also been described in some rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers.<ref name=":0" /> This overexpression is caused by deregulations at a transcriptional and posttranscriptional level.<ref name=":1" />
⚫
==References==

Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells, which leads to Trop-2 being associated with tumor aggressiveness and poor prognosis. This is also confirmed by the fact, that the proliferation of tumor cells is disturbed when Trop-2 is knocked down. These facts make Trop-2 a possible prognostic biomarker to identify high-risk patients, as well as an attractive therapeutic target for late-stage diseases<ref name=":1" />

This antigen is the target of [[sacituzumab govitecan]] and [[datopotamab deruxtecan]] (Dato-DXd),<ref>Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial[https://www.astrazeneca.com/media-centre/press-releases/2024/dato-dxd-improved-os-in-nonsquamous-lung-cancer.html]</ref> both [[antibody-drug conjugate]]s.

⚫
== References ==
{{reflist}}
{{reflist}}
⚫
==Further reading==
⚫
{{refbegin | 2}}
{{PBB_Further_reading
| citations =
⚫
*{{cite journal |vauthors=Linnenbach AJ, Wojcierowski J, Wu SA, etal |title=Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=86 |issue= 1 |pages= 27–31 |year= 1989 |pmid= 2911574 |doi=10.1073/pnas.86.1.27 | pmc=286396 }}
⚫
*{{cite journal |vauthors=Fornaro M, Dell'Arciprete R, Stella M, etal |title=Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. |journal=Int. J. Cancer |volume=62 |issue= 5 |pages= 610–8 |year= 1995 |pmid= 7665234 |doi=10.1002/ijc.2910620520 }}
⚫
*{{cite journal | author=[[Elsewedy Electric]] T, Fornaro M, Alberti S |title=Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. |journal=Int. J. Cancer |volume=75 |issue= 2 |pages= 324–30 |year= 1998 |pmid= 9462726 |doi=10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B }}
⚫
*{{cite journal | author=Ripani E, Sacchetti A, Corda D, Alberti S |title=Human Trop-2 is a tumor-associated calcium signal transducer. |journal=Int. J. Cancer |volume=76 |issue= 5 |pages= 671–6 |year= 1998 |pmid= 9610724 |doi=10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 }}
⚫
*{{cite journal |vauthors=Tsujikawa M, Kurahashi H, Tanaka T, etal |title=Identification of the gene responsible for gelatinous drop-like corneal dystrophy. |journal=Nat. Genet. |volume=21 |issue= 4 |pages= 420–3 |year= 1999 |pmid= 10192395 |doi= 10.1038/7759 }}
⚫
*{{cite journal |vauthors=Nakamura T, Nishida K, Dota A, etal |title=Gelatino-lattice corneal dystrophy: clinical features and mutational analysis. |journal=Am. J. Ophthalmol. |volume=129 |issue= 5 |pages= 665–6 |year= 2000 |pmid= 10844062 |doi=10.1016/S0002-9394(00)00369-X }}
⚫
*{{cite journal |vauthors=Kinoshita S, Nishida K, Dota A, Abbie F, etal |title=Epithelial barrier function and ultrastructure of gelatinous drop-like corneal dystrophy. |journal=Cornea |volume=19 |issue= 4 |pages= 551–5 |year= 2000 |pmid= 10928776 |doi=10.1097/00003226-200007000-00029 }}
⚫
*{{cite journal |vauthors=Tsujikawa M, Tsujikawa K, Maeda N, etal |title=Rapid detection of M1S1 mutations by the protein truncation test. |journal=Invest. Ophthalmol. Vis. Sci. |volume=41 |issue= 9 |pages= 2466–8 |year= 2000 |pmid= 10937555 |doi= }}
⚫
*{{cite journal |vauthors=Ha NT, Fujiki K, Hotta Y, etal |title=Q118X mutation of M1S1 gene caused gelatinous drop-like corneal dystrophy: the P501T of BIGH3 gene found in a family with gelatinous drop-like corneal dystrophy. |journal=Am. J. Ophthalmol. |volume=130 |issue= 1 |pages= 119–20 |year= 2000 |pmid= 11004271 |doi=10.1016/S0002-9394(00)00596-1 }}
⚫
*{{cite journal |vauthors=Tasa G, Kals J, Muru K, etal |title=A novel mutation in the M1S1 gene responsible for gelatinous droplike corneal dystrophy. |journal=Invest. Ophthalmol. Vis. Sci. |volume=42 |issue= 12 |pages= 2762–4 |year= 2001 |pmid= 11687514 |doi= }}
⚫
*{{cite journal |vauthors=Yoshida S, Kumano Y, Yoshida A, etal |title=Two brothers with gelatinous drop-like dystrophy at different stages of the disease: role of mutational analysis. |journal=Am. J. Ophthalmol. |volume=133 |issue= 6 |pages= 830–2 |year= 2002 |pmid= 12036680 |doi=10.1016/S0002-9394(02)01407-1 }}
⚫
*{{cite journal |vauthors=Ren Z, Lin PY, Klintworth GK, etal |title=Allelic and locus heterogeneity in autosomal recessive gelatinous drop-like corneal dystrophy. |journal=Hum. Genet. |volume=110 |issue= 6 |pages= 568–77 |year= 2002 |pmid= 12107443 |doi= 10.1007/s00439-002-0729-z }}
*{{cite journal |vauthors=Strausberg RL, Feingold EA, Grouse LH, etal |title=Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue= 26 |pages= 16899–903 |year= 2003 |pmid= 12477932 |doi= 10.1073/pnas.242603899 | pmc=139241 }}
⚫
*{{cite journal |vauthors=Ha NT, Chau HM, Cung le X, etal |title=A novel mutation of M1S1 gene found in a Vietnamese patient with gelatinous droplike corneal dystrophy. |journal=Am. J. Ophthalmol. |volume=135 |issue= 3 |pages= 390–3 |year= 2003 |pmid= 12614764 |doi=10.1016/S0002-9394(02)01952-9 }}
⚫
*{{cite journal |vauthors=Gires O, Eskofier S, Lang S, etal |title=Cloning and characterisation of a 1.1 kb fragment of the carcinoma-associated epithelial cell adhesion molecule promoter. |journal=Anticancer Res. |volume=23 |issue= 4 |pages= 3255–61 |year= 2003 |pmid= 12926061 |doi= }}
⚫
*{{cite journal |vauthors=Tian X, Fujiki K, Li Q, etal |title=Compound heterozygous mutations of M1S1 gene in gelatinous droplike corneal dystrophy. |journal=Am. J. Ophthalmol. |volume=137 |issue= 3 |pages= 567–9 |year= 2004 |pmid= 15013888 |doi= 10.1016/j.ajo.2003.08.008 }}
⚫
*{{cite journal |vauthors=Murakami A, Kimura S, Fujiki K, etal |title=Mutations in the membrane component, chromosome 1, surface marker 1 (M1S1) gene in gelatinous drop-like corneal dystrophy. |journal=Jpn. J. Ophthalmol. |volume=48 |issue= 4 |pages= 317–20 |year= 2004 |pmid= 15295654 |doi= 10.1007/s10384-003-0064-5 }}
*{{cite journal |vauthors=Gerhard DS, Wagner L, Feingold EA, etal |title=The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). |journal=Genome Res. |volume=14 |issue= 10B |pages= 2121–7 |year= 2004 |pmid= 15489334 |doi= 10.1101/gr.2596504 | pmc=528928 }}
}}
⚫
{{refend}}


⚫
== Further reading ==
<!-- The PBB_Controls template provides controls for Protein Box Bot, please see Template:PBB_Controls for details. -->
⚫
{{refbegin|30em}}
{{PBB_Controls
⚫
* {{cite journal | vauthors = Linnenbach AJ, Wojcierowski J, Wu SA, Pyrc JJ, Ross AH, Dietzschold B, Speicher D, Koprowski H | display-authors = 6 | title = Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733 | journal = Proceedings of the National Academy of Sciences of the United States of America | volume = 86 | issue = 1 | pages = 27–31 | date = January 1989 | pmid = 2911574 | pmc = 286396 | doi = 10.1073/pnas.86.1.27 | doi-access = free | bibcode = 1989PNAS...86...27L }}
| update_page = yes
⚫
* {{cite journal | vauthors = Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG, Alberti S | title = Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas | journal = International Journal of Cancer | volume = 62 | issue = 5 | pages = 610–618 | date = September 1995 | pmid = 7665234 | doi = 10.1002/ijc.2910620520 | s2cid = 23260113 }}
| require_manual_inspection = no
⚫
* {{cite journal | vauthors = El Sewedy T, Fornaro M, Alberti S | title = Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2 | journal = International Journal of Cancer | volume = 75 | issue = 2 | pages = 324–330 | date = January 1998 | pmid = 9462726 | doi = 10.1002/(SICI)1097-0215(19980119)75:2<324::AID-IJC24>3.0.CO;2-B | doi-access = free }}
| update_protein_box = yes
⚫
* {{cite journal | vauthors = Ripani E, Sacchetti A, Corda D, Alberti S | title = Human Trop-2 is a tumor-associated calcium signal transducer | journal = International Journal of Cancer | volume = 76 | issue = 5 | pages = 671–676 | date = May 1998 | pmid = 9610724 | doi = 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 | doi-access = free }}
| update_summary = no
⚫
* {{cite journal | vauthors = Tsujikawa M, Kurahashi H, Tanaka T, Nishida K, Shimomura Y, Tano Y, Nakamura Y | title = Identification of the gene responsible for gelatinous drop-like corneal dystrophy | journal = Nature Genetics | volume = 21 | issue = 4 | pages = 420–423 | date = April 1999 | pmid = 10192395 | doi = 10.1038/7759 | s2cid = 2275476 }}
| update_citations = yes
⚫
* {{cite journal | vauthors = Nakamura T, Nishida K, Dota A, Adachi W, Yamamoto S, Maeda N, Okada M, Kinoshita S | display-authors = 6 | title = Gelatino-lattice corneal dystrophy: clinical features and mutational analysis | journal = American Journal of Ophthalmology | volume = 129 | issue = 5 | pages = 665–666 | date = May 2000 | pmid = 10844062 | doi = 10.1016/S0002-9394(00)00369-X }}
}}
⚫
* {{cite journal | vauthors = Kinoshita S, Nishida K, Dota A, Inatomi T, Koizumi N, Elliott A, Lewis D, Quantock A, Fullwood N | display-authors = 6 | title = Epithelial barrier function and ultrastructure of gelatinous drop-like corneal dystrophy | journal = Cornea | volume = 19 | issue = 4 | pages = 551–555 | date = July 2000 | pmid = 10928776 | doi = 10.1097/00003226-200007000-00029 | s2cid = 43011710 }}
⚫
* {{cite journal | vauthors = Tsujikawa M, Tsujikawa K, Maeda N, Watanabe H, Inoue Y, Mashima Y, Shimomura Y, Tano Y | display-authors = 6 | title = Rapid detection of M1S1 mutations by the protein truncation test | journal = Investigative Ophthalmology & Visual Science | volume = 41 | issue = 9 | pages = 2466–2468 | date = August 2000 | pmid = 10937555 }}
⚫
* {{cite journal | vauthors = Ha NT, Fujiki K, Hotta Y, Nakayasu K, Kanai A | title = Q118X mutation of M1S1 gene caused gelatinous drop-like corneal dystrophy: the P501T of BIGH3 gene found in a family with gelatinous drop-like corneal dystrophy | journal = American Journal of Ophthalmology | volume = 130 | issue = 1 | pages = 119–120 | date = July 2000 | pmid = 11004271 | doi = 10.1016/S0002-9394(00)00596-1 }}
⚫
* {{cite journal | vauthors = Tasa G, Kals J, Muru K, Juronen E, Piirsoo A, Veromann S, Jänes S, Mikelsaar AV, Lang A | display-authors = 6 | title = A novel mutation in the M1S1 gene responsible for gelatinous droplike corneal dystrophy | journal = Investigative Ophthalmology & Visual Science | volume = 42 | issue = 12 | pages = 2762–2764 | date = November 2001 | pmid = 11687514 }}
⚫
* {{cite journal | vauthors = Yoshida S, Kumano Y, Yoshida A, Numa S, Yabe N, Hisatomi T, Nishida T, Ishibashi T, Matsui T | display-authors = 6 | title = Two brothers with gelatinous drop-like dystrophy at different stages of the disease: role of mutational analysis | journal = American Journal of Ophthalmology | volume = 133 | issue = 6 | pages = 830–832 | date = June 2002 | pmid = 12036680 | doi = 10.1016/S0002-9394(02)01407-1 }}
⚫
* {{cite journal | vauthors = Ren Z, Lin PY, Klintworth GK, Iwata F, Munier FL, Schorderet DF, El Matri L, Theendakara V, Basti S, Reddy M, Hejtmancik JF | display-authors = 6 | title = Allelic and locus heterogeneity in autosomal recessive gelatinous drop-like corneal dystrophy | journal = Human Genetics | volume = 110 | issue = 6 | pages = 568–577 | date = June 2002 | pmid = 12107443 | doi = 10.1007/s00439-002-0729-z | s2cid = 24052349 | url = https://zenodo.org/record/1232715 }}
⚫
* {{cite journal | vauthors = Ha NT, Chau HM, Cung LE, Thanh TK, Fujiki K, Murakami A, Kanai A | title = A novel mutation of M1S1 gene found in a Vietnamese patient with gelatinous droplike corneal dystrophy | journal = American Journal of Ophthalmology | volume = 135 | issue = 3 | pages = 390–393 | date = March 2003 | pmid = 12614764 | doi = 10.1016/S0002-9394(02)01952-9 }}
⚫
* {{cite journal | vauthors = Gires O, Eskofier S, Lang S, Zeidler R, Münz M | title = Cloning and characterisation of a 1.1 kb fragment of the carcinoma-associated epithelial cell adhesion molecule promoter | journal = Anticancer Research | volume = 23 | issue = 4 | pages = 3255–3261 | year = 2003 | pmid = 12926061 }}
⚫
* {{cite journal | vauthors = Tian X, Fujiki K, Li Q, Murakami A, Xie P, Kanai A, Wang W, Liu Z | display-authors = 6 | title = Compound heterozygous mutations of M1S1 gene in gelatinous droplike corneal dystrophy | journal = American Journal of Ophthalmology | volume = 137 | issue = 3 | pages = 567–569 | date = March 2004 | pmid = 15013888 | doi = 10.1016/j.ajo.2003.08.008 }}
⚫
* {{cite journal | vauthors = Murakami A, Kimura S, Fujiki K, Fujimaki T, Kanai A | title = Mutations in the membrane component, chromosome 1, surface marker 1 (M1S1) gene in gelatinous drop-like corneal dystrophy | journal = Japanese Journal of Ophthalmology | volume = 48 | issue = 4 | pages = 317–320 | year = 2004 | pmid = 15295654 | doi = 10.1007/s10384-003-0064-5 | s2cid = 28358081 }}
⚫
{{refend}}




Latest revision as of 20:12, 9 October 2024

TACSTD2
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
AliasesTACSTD2, EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1, TROP2, tumor-associated calcium signal transducer 2, tumor associated calcium signal transducer 2
External IDsOMIM: 137290; MGI: 1861606; HomoloGene: 1763; GeneCards: TACSTD2; OMA:TACSTD2 - orthologs
Orthologs
SpeciesHumanMouse
Entrez

4070

56753

Ensembl

ENSG00000184292

ENSMUSG00000051397

UniProt

P09758

Q8BGV3

RefSeq (mRNA)

NM_002353

NM_020047

RefSeq (protein)

NP_002344

NP_064431

Location (UCSC)Chr 1: 58.58 – 58.58 MbChr 6: 67.51 – 67.51 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Tumor-associated calcium signal transducer 2, also known as Trop-2 and as epithelial glycoprotein-1 antigen (EGP-1)[5] is a protein that in humans is encoded by the TACSTD2 gene.[6][7][8]

This intronless gene is located at the short arm of chromosome 1 (1p32.1).[9] It encodes a carcinoma-associated antigen defined by the monoclonal antibody GA733. This antigen is a member of a family including at least two type I membrane proteins. It transduces an intracellular calcium signal and acts as a cell surface receptor.

Mutations of this gene result in gelatinous drop-like corneal dystrophy, an autosomal recessive disorder characterized by severe corneal amyloidosis leading to blindness.[8]

Trop-2 expression was originally described in trophoblasts (placenta) and fetal tissues (e.g., lung). Later, its expression was also described in the normal stratified squamous epithelium of the skin, uterine cervix, esophagus, and tonsillar crypts.[10]

Trop-2 plays a role in tumor progression by actively interacting with several key molecular signaling pathways traditionally associated with cancer development and progression. Aberrant overexpression of Trop-2 has been described in several solid cancers, such as colorectal, renal, lung, and breast cancers. Trop-2 expression has also been described in some rare and aggressive malignancies, e.g., salivary duct, anaplastic thyroid, uterine/ovarian, and neuroendocrine prostate cancers.[10] This overexpression is caused by deregulations at a transcriptional and posttranscriptional level.[9]

Trop-2 causes cancer cell growth, proliferation, invasion, migration, and survival of cancer cells, which leads to Trop-2 being associated with tumor aggressiveness and poor prognosis. This is also confirmed by the fact, that the proliferation of tumor cells is disturbed when Trop-2 is knocked down. These facts make Trop-2 a possible prognostic biomarker to identify high-risk patients, as well as an attractive therapeutic target for late-stage diseases[9]

This antigen is the target of sacituzumab govitecan and datopotamab deruxtecan (Dato-DXd),[11] both antibody-drug conjugates.

References

[edit]
  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000184292 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000051397 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Immunomedics Awarded Fast Track Designation by FDA for Sacituzumab Govitecan (IMMU-132) for Triple-Negative Breast Cancer Therapy [1]
  6. ^ Linnenbach AJ, Seng BA, Wu S, Robbins S, Scollon M, Pyrc JJ, et al. (March 1993). "Retroposition in a family of carcinoma-associated antigen genes". Molecular and Cellular Biology. 13 (3): 1507–1515. doi:10.1128/MCB.13.3.1507. PMC 359462. PMID 8382772.
  7. ^ Calabrese G, Crescenzi C, Morizio E, Palka G, Guerra E, Alberti S (Apr 2001). "Assignment of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridization". Cytogenetics and Cell Genetics. 92 (1–2): 164–165. doi:10.1159/000056891. PMID 11306819. S2CID 9708614.
  8. ^ a b "Entrez Gene: TACSTD2 tumor-associated calcium signal transducer 2".
  9. ^ a b c Wen, Ying; Ouyang, Dengjie; Zou, Qiongyan; Chen, Qitong; Luo, Na; He, Hongye; Anwar, Munawar; Yi, Wenjun (December 2022). "A literature review of the promising future of TROP2: a potential drug therapy target". Annals of Translational Medicine. 10 (24): 1403. doi:10.21037/atm-22-5976. ISSN 2305-5839. PMC 9843409. PMID 36660684.
  10. ^ a b Vranic S, Gatalica Z (February 2022). "Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers". Bosnian Journal of Basic Medical Sciences. 22 (1): 14–21. doi:10.17305/bjbms.2021.6100. PMC 8860310. PMID 34181512.
  11. ^ Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial[2]

Further reading

[edit]


Stub icon

This article on a gene on human chromosome 1 is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=TACSTD2&oldid=1250333608"